Cargando…

Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging

High-content imaging of tumor organoids (TOs) treated with therapeutic agents provides detailed cell viability readouts at the organoid level. In contrast, most used protocols provide one number per well. While requiring the use of inverted microscopy with an automated stage, this protocol can provi...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsen, Brian M., Cancino, Andrea, Shaxted, Jenna M., Salahudeen, Ameen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127194/
https://www.ncbi.nlm.nih.gov/pubmed/35620075
http://dx.doi.org/10.1016/j.xpro.2022.101407
_version_ 1784712296569765888
author Larsen, Brian M.
Cancino, Andrea
Shaxted, Jenna M.
Salahudeen, Ameen A.
author_facet Larsen, Brian M.
Cancino, Andrea
Shaxted, Jenna M.
Salahudeen, Ameen A.
author_sort Larsen, Brian M.
collection PubMed
description High-content imaging of tumor organoids (TOs) treated with therapeutic agents provides detailed cell viability readouts at the organoid level. In contrast, most used protocols provide one number per well. While requiring the use of inverted microscopy with an automated stage, this protocol can provide critical information about heterogeneous responses of TOs to various treatments. This protocol describes a technique for culturing and drug testing TOs using fluorescent indicators of cell viability with high reproducibility. For complete details on the use and execution of this protocol, please refer to Larsen et al. (2021).
format Online
Article
Text
id pubmed-9127194
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91271942022-05-25 Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging Larsen, Brian M. Cancino, Andrea Shaxted, Jenna M. Salahudeen, Ameen A. STAR Protoc Protocol High-content imaging of tumor organoids (TOs) treated with therapeutic agents provides detailed cell viability readouts at the organoid level. In contrast, most used protocols provide one number per well. While requiring the use of inverted microscopy with an automated stage, this protocol can provide critical information about heterogeneous responses of TOs to various treatments. This protocol describes a technique for culturing and drug testing TOs using fluorescent indicators of cell viability with high reproducibility. For complete details on the use and execution of this protocol, please refer to Larsen et al. (2021). Elsevier 2022-05-18 /pmc/articles/PMC9127194/ /pubmed/35620075 http://dx.doi.org/10.1016/j.xpro.2022.101407 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Protocol
Larsen, Brian M.
Cancino, Andrea
Shaxted, Jenna M.
Salahudeen, Ameen A.
Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging
title Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging
title_full Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging
title_fullStr Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging
title_full_unstemmed Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging
title_short Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging
title_sort protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127194/
https://www.ncbi.nlm.nih.gov/pubmed/35620075
http://dx.doi.org/10.1016/j.xpro.2022.101407
work_keys_str_mv AT larsenbrianm protocolfordrugscreeningofpatientderivedtumororganoidsusinghighcontentfluorescentimaging
AT cancinoandrea protocolfordrugscreeningofpatientderivedtumororganoidsusinghighcontentfluorescentimaging
AT shaxtedjennam protocolfordrugscreeningofpatientderivedtumororganoidsusinghighcontentfluorescentimaging
AT salahudeenameena protocolfordrugscreeningofpatientderivedtumororganoidsusinghighcontentfluorescentimaging